T
GILD icon

Transce3nd’s Gilead Sciences GILD Stock Holding History

Transce3nd’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-302
Closed -$33.5K – 542
2025
Q2 		$33.5K Sell
302
-500
-62% -$53.2K 0.01% 363
2025
Q1 		$89.9K Sell
802
-270
-25% -$27.9K 0.04% 208
2024
Q4 		$99K Buy
+1,072
New +$96.5K 0.03% 256

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Transce3nd's GILD Position: Q3 2025 in Review

Transce3nd sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 302 shares — an estimated $33.5K sold.

Transce3nd first reported a position in GILD in Q4 2024 and held it in 3 quarters. The position peaked at $99K in Q4 2024. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Transce3nd reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 302 Gilead Sciences shares in Q3 2025, an estimated $33.5K.
  • Transce3nd first reported a position in Gilead Sciences in Q4 2024 and held it in 3 quarters.
  • Transce3nd's Gilead Sciences position peaked at $99K in Q4 2024.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.